معرفی
Ranko Škrbić is a full professor at the Department of Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty of the University of Banja Luka. His primary roles include teaching and leading research in pharmacology and toxicology. He oversees academic programs spanning bachelor's, master's, and doctoral studies in medicine.
His research focuses on drug mechanisms, cardiovascular pharmacology, inflammation modulation, and metabolic disease interventions. Notable areas include the cardioprotective effects of GLP-1 receptor agonists (e.g., liraglutide), bile acid therapies for organ protection, and drug degradation kinetics. He also investigates placental biology, smoking cessation strategies in surgical patients, and nanomaterial biocompatibility.
Dr. Škrbić has published extensively in peer-reviewed journals, with over 100 articles since 2001. His work spans cardiovascular pharmacology, drug development, and clinical trials. He collaborates internationally, including with institutions like the University of Essen and Fairnetzen Foundation. No specific awards are listed, but his prolific research output reflects significant contributions to his field.
His advising and grants focus on translational research, with projects funded by organizations like the National Science Fund of Serbia. He leads teams exploring drug mechanisms in sepsis, diabetes, and inflammatory bowel disease. Collaborations include work on graphene-based biomedical materials and 3D-QSAR modeling for TRPA1 agonists.
